Intellectual Property Office Home University of Cincinnati
News
Technologies
Issued US Patents
UC Technology Startups
Forms
Our Mission
IP Overview
Patents
Copyright
Licensing
Conflicts
Policies and Law
Annual Reports
Staff and Location
Contact Us
Links
UC Directory
IPO Home

Case Number 106042 - Methods for Diagnosing and Treating Cancers via manipulations of a non-degradative pVHL-Rpb1 ubiquitylation pathway

Description:  The novel pathway controlling RCCC tumorogenesis involves pVHL-dependent modulation of the large subunit of RNA Polymerase II, Rpb1. Low grade oxidative stress, a common pathophysiological factor in cancer, induces multiple pVHL-dependent Rpb1 modifications including P1465 hydroxylation, phosphorylation of Serine 5 within the C-terminal domain (CTD), and polyubiquitylation which does not lead to protein degradation.
RCCC cells carrying a non-hydroxylatable Rpb1 mutant (P1465) showed significantly enhanced proliferation in culture and enhanced tumoroginesis when injected into nude mice. Human RCCC tumors show alterations in Rpb1 P1465 hydroxylation, serine 5 phosphorylation and ubiquitylation. Thus, these modifications may be very useful biomarkers for detecting cancer and assessing tumor grade. In addition, the specific hydroxylases and kinases that modify Rpb1 may be effective targets for therapeutic intervention. Work is underway to identify the Rpb1 specific modulators.

A US patent application is pending.


For more information please contact Kellen Sensor at 513-558-5621 or Kellen.Sensor@uc.edu



Back to Technologies
 
Printer Friendly Version of Methods for Diagnosing and Treating Cancers via manipulations of a non-degradative  pVHL-Rpb1 ubiquitylation pathway - 106042









Copyright Information © Copyright 2004-2012 university of Cincinnati, Ohio. All rights reserved.